Xenon Pharmaceuticals Inc.
XENE
Xếp hạng trong cổ phiếu
#4604
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Giá cổ phiếu
$34.22
Vốn hóa thị trường
$3.31B
Thay đổi (1 ngày)
2.16%
Thay đổi (1 năm)
-17.81%
Quốc gia
CA
Giao dịch Xenon Pharmaceuticals Inc. (XENE)
Danh mục
Healthcare
EPS của Xenon Pharmaceuticals Inc. (XENE)
EPS tính đến June 2026 TTM: $-4.74
Theo các báo cáo tài chính mới nhất và giá cổ phiếu của Xenon Pharmaceuticals Inc., EPS hiện tại của công ty (TTM) là $-4.74. Vào cuối năm 2023, công ty có EPS là $-2.73, tăng so với EPS năm 2022 là $-2.06.
Lịch sử EPS của Xenon Pharmaceuticals Inc. từ 2011 đến 2026
EPS vào cuối mỗi năm
| Năm | EPS | Thay đổi |
|---|---|---|
| 2026 (TTM) | $-4.74 | 57.48% |
| 2024 | $-3.01 | 10.26% |
| 2023 | $-2.73 | 32.52% |
| 2022 | $-2.06 | 16.38% |
| 2021 | $-1.77 | 113.25% |
| 2020 | $-0.83 | -46.10% |
| 2019 | $-1.54 | -13.48% |
| 2018 | $-1.78 | 4.09% |
| 2017 | $-1.71 | 15.54% |
| 2016 | $-1.48 | 34.55% |
| 2015 | $-1.10 | -217.02% |
| 2014 | $0.94 | 123.81% |
| 2013 | $0.42 | -113.00% |
| 2012 | $-3.23 | -64.19% |
| 2011 | $-9.02 | 0.00% |
EPS cho các công ty hoặc đối thủ cạnh tranh tương tự
| Công ty | EPS | Chênh lệch EPS | Quốc gia |
|---|---|---|---|
| $17.32 | -465.40% |
US
|
|
| $-7.98 | 68.35% |
US
|
|
| $-5.29 | 11.60% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -685.23% |
NL
|
